KCM
IRD

Knoll Capital Management’s Opus Genetics IRD Stock Holding History

Knoll Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-45
Closed -$53 – 38
2024
Q4 		$53 Sell
45
-99,955
-100% -$115K ﹤0.01% 35
2024
Q3 		$131K Hold
100,000
– – 0.06% 35
2024
Q2 		$153K Hold
100,000
– – 0.1% 35
2024
Q1 		$201K Hold
100,000
– – 0.13% 33
2023
Q4 		$301K Hold
100,000
– – 0.25% 32
2023
Q3 		$335K Hold
100,000
– – 0.35% 34
2023
Q2 		$434K Hold
100,000
– – 0.53% 26
2023
Q1 		$375K Buy
+100,000
New +$359K 0.58% 25

Other funds holding IRD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Knoll Capital Management's IRD Position: Q1 2025 in Review

Knoll Capital Management sold out of Opus Genetics (IRD) in Q1 2025, closing a stake of 45 shares — an estimated $53 sold.

Knoll Capital Management first reported a position in IRD in Q1 2023 and held it in 8 quarters. The position peaked at $434K in Q2 2023. 46 funds tracked by Wall St. Rank hold IRD as of Q1 2025.

  • Knoll Capital Management reported no remaining Opus Genetics position as of Q1 2025 after selling out during the quarter.
  • Knoll Capital Management sold 45 Opus Genetics shares in Q1 2025, an estimated $53.
  • Knoll Capital Management first reported a position in Opus Genetics in Q1 2023 and held it in 8 quarters.
  • Knoll Capital Management's Opus Genetics position peaked at $434K in Q2 2023.
  • 46 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2025.

Based on Knoll Capital Management's 13F filing for Q1 2025, filed 15 May 2025.